Relating to gender-affirming treatment; declaring an emergency.
House Bill 3338 directs the Oregon Health Evidence Review Commission (HERC) to begin a medical technology assessment of gender-affirming treatment no later than August 30, 2025. The assessment must use the commission’s evidence-based review process and develop health care guidelines for providers, consumers, and purchasers in Oregon. The bill defines gender-affirming treatment broadly to include procedures, services, drugs, devices, and products used to treat incongruence between gender identity and sex assigned at birth.
The required review must examine diagnostic criteria and assessment procedures, and evaluate the safety, efficacy, quality of evidence, and strength of evidence for gender-affirming treatment across children, adolescents, and adults. The bill specifically lists puberty blockers, hormone replacement therapy, chest surgeries, genital surgeries, tracheal shave, hair electrolysis, and facial feminization or other facial gender-affirming treatments as topics for review. HERC must report its findings to legislative health committees by September 15, 2026, and publish the report on the Oregon Health Authority website. The measure is temporary, repealed on January 2, 2027, and takes effect immediately upon passage because it declares an emergency.
HB 3338 would not directly change eligibility rules or coverage mandates in existing law, but it would require HERC to conduct a formal evidence review that could inform future state health policy, clinical guidance, and payer decisions regarding gender-affirming care. It creates a new, time-limited statutory duty for the commission and requires public reporting, thereby adding an official state review process for a politically and medically contested area of health care.
Based on the bill text and the absence of recorded committee testimony or votes, the available context suggests the measure is framed as an evidence-based health policy review rather than an immediate substantive restriction or expansion of care. The emergency clause indicates sponsors viewed the issue as urgent. Because no committee discussion or voting history is provided, there is no documented legislative sentiment beyond the bill’s neutral, research-oriented structure.
The main point of contention likely concerns the scope and purpose of the mandated review of gender-affirming treatment, especially because the bill explicitly includes treatments for minors as well as adults and names specific interventions such as puberty blockers, hormones, and surgeries. Supporters may view the measure as a neutral evidence assessment to guide policy, while critics could see it as a mechanism that may be used to question or limit access to gender-affirming care. No recorded testimony is available here to identify specific legislators, advocates, or opponents.